Men who use AndroGel and other prescription testosterone treatments may be in danger of experiencing a serious blood clot, including pulmonary embolism. Since January 2014, the U.S. Food & Drug Administration (FDA) has issued several warnings regarding the cardiovascular side effects potentially associated with Low-T therapy.
Thousands of men have filed testosterone lawsuits in order to obtain compensation for heart attacks, stroke, blood clots, and other cardiovascular complications allegedly associated with the use of low-T therapy. If you would like to learn more about the compensation that could be available to men who allegedly suffered a testosterone-related pulmonary embolism, please call (888) 994-5118 to arrange for a free, no-obligation case review with the legal team at Bernstein Liebhard LLP.
Prescription testosterone medications are approved to treat men who suffer from hypogonadism, or low testosterone, that results from another underlying illness or medical condition. However, the use of such products has spiked sharply since they were first launched on the market, driven by advertising that some say positions the medications as a way to combat the effects of male aging.
Low testosterone therapy medications currently approved by the FDA include:
On January 31, 2014, the FDA announced it was reviewing the safety of these drugs, after two studies indicated they could increase cardiovascular risks in certain men:
The FDA would complete its review its review in March 2015, and order all low-T manufacturers to include heart attack and stroke warnings on their product labels. The agency also mandated that the labels clearly state that the drugs haven’t been shown to be safe or effective in treating age-related hypogonadism. Read More
In June 2014, the FDA announced that the labeling for prescription testosterone medications would be updated to include information about their association with venous blood clots, including pulmonary embolism. The agency did note that the prescribing information for low testosterone therapies already includes notice of a risk of venous blood clots that are associated with the development of a condition called polycythemia. However, the FDA was requiring the manufacturers to modify the labels with a more general warning in light of reports of testosterone patients who experienced blood clots in the absence of this condition. Read More
A pulmonary embolism is a blood clot that forms deep in the veins of the leg and travels to the lung, where it blocks the pulmonary artery. Symptoms of pulmonary emboli include:
These types of blood clots are always life-threatening, and require immediate medical treatment.
There is still time for the alleged victims of testosterone-related pulmonary embolism to file their own lawsuits against the manufacturers of low-T therapies. To learn more about this growing litigation, please contact our attorneys today, by calling (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.